University of Texas Texas AM Investment Managment Co. Makes New $653,000 Investment in Denali Therapeutics Inc. (NASDAQ:DNLI)

University of Texas Texas AM Investment Managment Co. bought a new position in Denali Therapeutics Inc. (NASDAQ:DNLIFree Report) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 30,428 shares of the company’s stock, valued at approximately $653,000. Denali Therapeutics makes up about 0.3% of University of Texas Texas AM Investment Managment Co.’s holdings, making the stock its 8th biggest position.

Other hedge funds and other institutional investors have also bought and sold shares of the company. CWM LLC boosted its stake in shares of Denali Therapeutics by 216.7% during the fourth quarter. CWM LLC now owns 2,011 shares of the company’s stock valued at $43,000 after purchasing an additional 1,376 shares during the period. Fisher Asset Management LLC purchased a new stake in shares of Denali Therapeutics during the fourth quarter valued at approximately $59,000. Assetmark Inc. boosted its stake in shares of Denali Therapeutics by 65.3% during the fourth quarter. Assetmark Inc. now owns 3,550 shares of the company’s stock valued at $76,000 after purchasing an additional 1,402 shares during the period. Brandywine Managers LLC purchased a new stake in shares of Denali Therapeutics during the fourth quarter valued at approximately $206,000. Finally, Quest Partners LLC purchased a new stake in shares of Denali Therapeutics during the fourth quarter valued at approximately $214,000. Hedge funds and other institutional investors own 92.92% of the company’s stock.

Analysts Set New Price Targets

DNLI has been the subject of a number of recent analyst reports. Stifel Nicolaus decreased their target price on Denali Therapeutics from $26.00 to $22.00 and set a “hold” rating for the company in a report on Wednesday, May 8th. HC Wainwright restated a “buy” rating and set a $95.00 target price on shares of Denali Therapeutics in a report on Wednesday, May 8th. The Goldman Sachs Group decreased their target price on Denali Therapeutics from $73.00 to $50.00 and set a “buy” rating for the company in a report on Thursday, February 29th. UBS Group decreased their price objective on Denali Therapeutics from $70.00 to $32.00 and set a “buy” rating for the company in a report on Tuesday, April 9th. Finally, Wedbush decreased their price objective on Denali Therapeutics from $31.00 to $30.00 and set an “outperform” rating for the company in a report on Wednesday, May 8th. One research analyst has rated the stock with a hold rating and eight have assigned a buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $40.22.

Read Our Latest Report on Denali Therapeutics

Denali Therapeutics Stock Down 6.3 %

DNLI traded down $1.39 on Friday, hitting $20.73. 1,047,522 shares of the company’s stock traded hands, compared to its average volume of 1,036,063. The company’s 50 day simple moving average is $18.65 and its 200-day simple moving average is $19.08. Denali Therapeutics Inc. has a one year low of $14.56 and a one year high of $33.31.

Denali Therapeutics (NASDAQ:DNLIGet Free Report) last released its quarterly earnings data on Tuesday, May 7th. The company reported ($0.68) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.69) by $0.01. Denali Therapeutics had a negative return on equity of 11.46% and a negative net margin of 36.51%. During the same period in the prior year, the business posted ($0.80) EPS. Research analysts expect that Denali Therapeutics Inc. will post -2.78 earnings per share for the current fiscal year.

Insider Transactions at Denali Therapeutics

In related news, Director Jennifer E. Cook sold 1,458 shares of the company’s stock in a transaction dated Thursday, June 6th. The stock was sold at an average price of $21.73, for a total transaction of $31,682.34. Following the transaction, the director now directly owns 20,038 shares of the company’s stock, valued at approximately $435,425.74. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. In other news, Director Jennifer E. Cook sold 1,458 shares of the stock in a transaction dated Thursday, June 6th. The stock was sold at an average price of $21.73, for a total value of $31,682.34. Following the transaction, the director now directly owns 20,038 shares of the company’s stock, valued at $435,425.74. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Steve E. Krognes sold 92,500 shares of the stock in a transaction dated Monday, April 1st. The shares were sold at an average price of $20.50, for a total value of $1,896,250.00. Following the completion of the transaction, the director now directly owns 47,341 shares in the company, valued at $970,490.50. The disclosure for this sale can be found here. In the last three months, insiders sold 95,624 shares of company stock valued at $1,958,403. Corporate insiders own 7.90% of the company’s stock.

About Denali Therapeutics

(Free Report)

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.

Featured Articles

Want to see what other hedge funds are holding DNLI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Denali Therapeutics Inc. (NASDAQ:DNLIFree Report).

Institutional Ownership by Quarter for Denali Therapeutics (NASDAQ:DNLI)

Receive News & Ratings for Denali Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Denali Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.